TuHURA Biosciences reported on its third quarter of 2025, highlighting progress in its clinical development programs, particularly the Phase 3 trial for IFx-2.0 in Merkel cell carcinoma and the upcoming Phase 2 study for TBS-2025. The company also saw scientific validation for its Delta Opioid Receptor technology with presentations accepted at the ASH meeting.
Phase 3 pivotal trial of IFx-2.0 as adjunctive therapy to pembrolizumab in first line treatment of advanced or metastatic MCC is underway, conducted under SPA agreement with the FDA.
positiveCompany's Delta Opioid Receptor (DOR) technology selected for an oral presentation at the 67th Annual American Society of Hematology (ASH) Annual Meeting.
positiveAppointment of Dr. Michael Turner as Vice President of Immunology, strengthening the TuHURA team.
positiveEntered into agreement for an At-The-Market (ATM) facility of up to $50 Million.
neutralResearch and development expenses increased to $4.9 million in Q3 2025 from $2.9 million in Q3 2024.
attentionNet cash outflows from operating activities increased to ($22.1) million in the nine months ended September 30, 2025, from ($12.1) million in the prior year period.
negativeMargin metrics will be available once backend extracts data from insights_json
TuHURA remains highly focused on the execution of its clinical development programs.
The Phase 3 pivotal trial of IFx-2.0 has the potential for both accelerated and regular approval.
Working with experts to complete protocol design for Phase 2 study of TBS-2025.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.